PDCD1LG2 and breast carcinoma: By conducting immunohistochemistry, we demonstrated that positive PD-L2 expression was presented in 329 (79.09%) out of 416 breast cancer samples, weak expression was seen in 192 (46.15%) of the patients, and strong expression was observed in 137 (32.93%) of the patients.